TNX-102 SL + Placebo SL Tablet

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Mar 27, 2017 → Jul 27, 2018

NCT ID

NCT03062540

About TNX-102 SL + Placebo SL Tablet

TNX-102 SL + Placebo SL Tablet is a phase 3 stage product being developed by Tonix Pharmaceuticals for PTSD. The current trial status is terminated. This product is registered under clinical trial identifier NCT03062540. Target conditions include PTSD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05472090	Phase 2	Completed	Aug 18, 2022	Jul 27, 2023	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
NCT04508621	Phase 3	Completed	Jul 22, 2020	Nov 1, 2021	Fibromyalgia
NCT04172831	Phase 3	Completed	Dec 9, 2019	Oct 29, 2020	Fibromyalgia
NCT03062540	Phase 3	Terminated	Mar 27, 2017	Jul 27, 2018	PTSD

Competing Products

11 competing products in PTSD

See all competitors

Product	Company	Stage	Hype Score
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	52
Quetiapine + Placebo	Johnson & Johnson	Approved	85
Lu AG06466 + Placebo	Lundbeck	Phase 1	30
Mifepristone 1200 mg daily + Placebo	Corcept Therapeutics	Phase 2	47
TNX-102 SL	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL 5.6 mg	Tonix Pharmaceuticals	Phase 3	69
TNX-102 SL + Placebo	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL + Placebo	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL + Placebo SL Tablets	Tonix Pharmaceuticals	Phase 3	69
TNX-102 SL	Tonix Pharmaceuticals	Phase 3	69
Ganaxolone + Placebo	Brain Biotech	Phase 2	44

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3

TNX-102 SL 5.6 mgPhase 3

TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3

TNX-102 SL Tablet, 2.8mg + Placebo SL TabletPhase 3

TNX-102 SL Tablet 2.8 mgPhase 3